Home/Pipeline/af-001

af-001

Thyroid Cancer (Radioiodine-Naïve)

Phase 1Active

Key Facts

Indication
Thyroid Cancer (Radioiodine-Naïve)
Phase
Phase 1
Status
Active
Company

About Alpha Fusion

A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.

View full company profile

Therapeutic Areas